Cofactor's kit will be used to characterize the immune responses generated in reaction to treatment with an investigational personalized cancer vaccine.
TwoXAR's proprietary artificial intelligence technology uses a variety of biomedical data including genomic, proteomic, and clinical data for drug discovery.
In this arm of the trial, 23 percent of patients treated with AKT1 E17K mutations saw their tumors shrink, a better result than those seen in three other trial arms.
During the meeting, researchers presented studies on combination immunotherapies and the efficacy of giving molecularly-informed treatments earlier in the disease continuum.
Screening of disease-linked cell types might bolster drug discovery efforts in schizophrenia, according to a proof-of-concept study.
The new RNA sequencing analysis workflow integrates Roche's RNA-seq library kits with Genialis' automated data processing pipeline for gene expression analyses.
The phenome-wide association study focused on SNPs near potential drug target sites with ties to one or more phenotypes that might impact target suitability.
The agency issued draft guidance on minimal residual disease as a biomarker and finalized another guidance on developing drugs with pan-cancer indications.
Using samples from different points in patients' treatment, researchers employed a variety of tools, including NanoString's GeoMx DSP, to explore potential response markers.
New data has shown that the firm's platform could help stratify patients for treatment with antibody-drug conjugates by finding those whose CTCs express enough of the target.
Centogene will collect dried blood spot samples and perform genetic analysis to find and recruit Parkinson's disease patients for Denali's LRRK2 inhibitor trials.
The firm's suite of tests, based on its Factorial system, produce cellular signatures offering clues to a compound's toxicity and the types of pathways it perturbs.
KMPJM will provide diagnostic and prognostic testing services based on genes, proteins, and other molecules to aid physicians in assessing and treating patients.
The agreement is part of a larger effort by the company to apply its Signabody affinity reagents to toxicity biomarker work and other areas of drug development.
The funding is being provided by three charities under a program designed to facilitate collaboration between research groups from different institutions.
The Durham, North Carolina-based startup's platform uses an image-based, tissue box-sized tool that cultures cells to capture long-term phenotypic behavior.
An analysis of naturally occurring alleles in the lipoprotein lipase pathway found that they and LDL-C-linked alleles affect disease risk independently.
The planned program is part of beta test of Repositive’s Cancer Models platform which connects biopharmaceutical companies and contract research organizations.
The firm will use the funds to advance its high-throughput single-cell analysis platform to analyze heterogeneity in cell populations for research and drug discovery.
UMich's Arul Chinnaiyan plans to use the funding to develop new tools and technologies to identify biomarkers for cancer diagnosis and treatment.
Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.
Wired reports that researchers have shown they could reprogram a DNA-based computer.
Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.
In Science this week: whole-genome sequencing of single sperm cells, and more.